title: Otlertuzumab more than a TRU(E) toddler in CLL?
authors.affiliation: KLINIKUM SCHWABING;
authors.forename: Clemens-Martin
authors.initials: CM
authors.lastname: Wendtner
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D011993:Recombinant Fusion Proteins / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D007074:Immunoglobulin G; D011993:Recombinant Fusion Proteins; C547387:TRU 016